PACTR201305000552290Completed未知
MONITORING THE EFFICACY AND THE SAFETY OF THREE ARTEMISININ COMBINATIONS THERAPIES (ACT) IN SENEGAL: RESULTS FROM TWO YEARS SURVEILLANCE
niversity Cheikh Anta DIOP of Dakar0 sites450 target enrollmentStarted: May 15, 2013Last updated:
Conditions
Trial Snapshot
- Phase
- 未知
- Status
- Completed
- Sponsor
- Enrollment
- 450
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
- Ages
- 1 Year(s) to 65 Year(s) (—)
- Sex
- All
Inclusion Criteria
- •Subjects aged over 6 months with the uncomplicated P. falciparum malaria,
- •Parasite density between 1000 and 100000 trophozoites/¿l,
- •Presence of an axillary temperature higher than 37.5° or history of fever during the previous 24 hours,
- •Ability to take oral medication and given her inform consent were included in the study
Exclusion Criteria
- •Patients presenting mono-infestation by another species or mixted infestation, severe vomiting, severe malnutrition, severe signs of malaria (such as severe anemia, convulsion, respiratory distress), women with positive pregnancy test and patients who had a history of allergy to study drugs or not given her inform consent were excluded in the study
Investigators
Similar Trials
Active, not recruiting
Not Applicable
ASSESSMENT OF THE EFFICACY AND SAFETY OF THREE CONCENTRATIONS: 1%, 0.3%, 0.1% OF CD5024 CREAM ONCE DAILY AND CD5024 1% CREAM TWICE DAILY, VERSUS ITS VEHICLE AND VERSUS METRONIDAZOLE 0.75% CREAM (ROZEX®), IN PATIENTS WITH PAPULO-PUSTULAR ROSACEA OVER 12 WEEKSPatients with papulo-pustular rosaceaMedDRA version: 9.0Level: LLTClassification code 10039218EUCTR2006-001999-20-CZGalderma Research & Development SNC270
Active, not recruiting
Not Applicable
ASSESSMENT OF THE EFFICACY AND SAFETY OF THREE CONCENTRATIONS: 1%, 0.3%, 0.1% OF CD5024 CREAM ONCE DAILY AND CD5024 1% CREAM TWICE DAILY, VERSUS ITS VEHICLE AND VERSUS METRONIDAZOLE 0.75% CREAM (ROZEX®), IN PATIENTS WITH PAPULO-PUSTULAR ROSACEA OVER 12 WEEKSEUCTR2006-001999-20-HUGalderma Research & Development SNC270
Active, not recruiting
Not Applicable
ASSESSMENT OF THE EFFICACY AND SAFETY OF THREE CONCENTRATIONS: 1%, 0.3%, 0.1% OF CD5024 CREAM ONCE DAILY AND CD5024 1% CREAM TWICE DAILY, VERSUS ITS VEHICLE AND VERSUS METRONIDAZOLE 0.75% CREAM (ROZEX®), IN PATIENTS WITH PAPULO-PUSTULAR ROSACEA OVER 12 WEEKSPatients with papulo-pustular rosaceaMedDRA version: 9.0Level: LLTClassification code 10039218EUCTR2006-001999-20-DEGalderma Research & Development SNC274
Not yet recruiting
Not Applicable
COMPARING SAFETY AND EFFICACY OF 3 DIFFERENT DOSES OF FENTANYL TO HEMODYNAMIC STRESS RESPONSE TO LARYNGOSCOPY AND INTUBATIOCTRI/2021/07/035113DEPARTMENT OF ANESTHESIOLOGY
Active, not recruiting
Phase 3
study to access effectiveness of new drug therapy (aspirin,atorvastatin and nicorandil) in covid-19CTRI/2021/04/032648Dr Ambudhar Sharma